Press coverage about Taro Pharmaceutical Industries (NYSE:TARO) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.4272171425369 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Taro Pharmaceutical Industries (NYSE TARO) traded up $4.00 on Wednesday, hitting $99.91. 78,558 shares of the company were exchanged, compared to its average volume of 99,192. Taro Pharmaceutical Industries has a one year low of $93.01 and a one year high of $128.46. The stock has a market capitalization of $3,929.19, a P/E ratio of 18.62 and a beta of 0.62.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/taro-pharmaceutical-industries-taro-getting-somewhat-favorable-news-coverage-report-finds.html.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.